Literature DB >> 19289224

Preventive migraine treatment.

Stephen D Silberstein1.   

Abstract

The pharmacologic treatment of migraine may be acute (abortive) or preventive (prophylactic), and patients with frequent severe headaches often require both approaches. Preventive therapy is used to try to reduce the frequency, duration, or severity of attacks. The preventive medications with the best-documented efficacy are amitriptyline, divalproex, topiramate, and the beta-blockers. Choice is made based on a drug's proven efficacy, the physician's informed belief about medications not yet evaluated in controlled trials, the drug's adverse events, the patient's preferences and headache profile, and the presence or absence of coexisting disorders. Because comorbid medical and psychologic illnesses are prevalent in patients who have migraine, one must consider comorbidity when choosing preventive drugs. Drug therapy may be beneficial for both disorders; however, it is also a potential confounder of optimal treatment of either.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289224     DOI: 10.1016/j.ncl.2008.11.007

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  19 in total

1.  Treatment of bipolar disorder with comorbid migraine.

Authors:  Abigail Ortiz; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

2.  Can topical beta blockers be successful for acute migraine management?

Authors:  Sophia M Chung
Journal:  Mo Med       Date:  2014 Jul-Aug

Review 3.  Prophylactic Treatment of Migraine.

Authors:  Azize Esra Gürsoy; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 4.  Management of psychiatric and neurological comorbidities in epilepsy.

Authors:  Andres M Kanner
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

5.  Preventive pharmacologic treatments for episodic migraine in adults.

Authors:  Tatyana A Shamliyan; Jae-Young Choi; Rema Ramakrishnan; Jennifer Biggs Miller; Shi-Yi Wang; Frederick R Taylor; Robert L Kane
Journal:  J Gen Intern Med       Date:  2013-04-17       Impact factor: 5.128

6.  Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-08       Impact factor: 6.200

7.  Preventive agents for migraine: focus on the antiepileptic drugs.

Authors:  R Shahien; K Beiruti
Journal:  J Cent Nerv Syst Dis       Date:  2012-02-26

8.  Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation.

Authors:  Marcus Gerwig; L Niehaus; P Stude; Z Katsarava; H C Diener
Journal:  J Headache Pain       Date:  2011-11-17       Impact factor: 7.277

Review 9.  Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus.

Authors:  Eduardo Rivera-Mancilla; Linda Al-Hassany; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

10.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.